Vaccine Design and Testing – News and Features

A new experimental vaccine developed by researchers could offer protection against emerging variants of SARS-CoV-2, as well as related coronaviruses, known as sarbecoviruses, that could spill over from animals to humans.

This article explores how broadly neutralizing antibodies are being researched, not only for their potential in the prevention of HIV, but also for other rapidly mutating viruses such as influenza and SARS-CoV-2.

For some HIV vaccines, repetitive immunizations lead to a chain reaction of antibody production against immune complexes already bound to viral proteins.

Researchers at Texas Biomed identified nine mutations in a bird flu strain from a person in Texas. Bad news: this strain is more capable of causing disease and replicates better in the brain. Good news: approved antivirals are still effective.

A large-scale study reveals genetic adaptations in a common bacteria found on the human body. Identifying mutations linked to immune evasion and antibiotic resistance could improve methods for diagnosing, preventing and treating infections.

Researchers have discovered that T cells can completely prevent viral infection, paving the way for new and more effective vaccines.

Headlines have been flooded with warnings of a surge in human metapneumovirus (hMPV) cases in China, but experts say the situation shouldn’t trigger fears of a larger pandemic threat.

Vaccine durability can, in part, be pinned on a surprising type of blood cell called megakaryocytes, and a new blood test can predict how long the vaccine response will last.

Researchers have modified lipid nanoparticles to enable them to cross the blood–brain barrier and target neural cells, marking a step toward next-generation treatments for neurological diseases.

The pathogen that causes sepsis has thwarted vaccines, but researchers now know why.